Icahn School of Medicine at Mount Sinai, New York, NY, USA; The New Jewish Home, New York, NY, USA; James J. Peters Veterans Affairs Medical Center, Bronx, NY, USA.
University of Rochester School of Medicine and Dentistry, Rochester, NY, USA; Geriatrics and Extended Care Data Analysis Center, US Department of Veterans Affairs, Washington, DC, USA.
Clin Ther. 2020 Apr;42(4):583-591. doi: 10.1016/j.clinthera.2020.02.016. Epub 2020 Mar 27.
Hypertension occurs in >50% of US nursing home (NH) residents, but it is unclear which antihypertensive classes offer the best balance of benefits and risks in this population. The objectives of this study were to describe the patterns of antihypertensive medication treatment in this population, focusing on thiazide diuretics, and to determine the association between thiazide diuretics (DIURs) and outcomes important to NH patients.
This observational cohort study was conducted in long-term NH residents treated for hypertension in the second quarter (Q2) of 2013, from all US NHs. The primary exposure was the frequency of use of antihypertensive treatment class (DIURs, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers [ARBs], calcium channel blockers, and β-blockers) according to Medicare Part D dispensing data. Because DIUR-related urinary symptoms were a focus, residents receiving nonthiazide diuretics were excluded. We ascertained continued medication use by class from Q2 to Q4 of 2013, and ascertained 6-month incontinence and hospitalization using data from Medicare claims and the Minimum Data Set.
Of 152,902 NH residents treated for hypertension, 52.2% were treated with β-blockers (22% as a single agent), 39.7% with calcium channel blockers (14% as a single agent), 38.8% with angiotensin-converting enzyme inhibitors (14% as a single agent), 14.2% with DIURs (2% as a single agent), and 13.2% with ARBs (4% as a single agent). Overall, 55.1% were treated with 1 drug; 33.2%, with 2 drugs; and 11.8%, with 3 or more drugs. From Q2 to Q4, DIURs were more likely to have been discontinued than any other class (19.4% vs 14.1%-16.1% for each of the other 4 classes; all, p < 0.05) and less likely to have been started than any other class except ARBs (1.4% vs 3.8%-5.3% for each of the other 3 classes). Urinary incontinence occurred in 76.6% of the sample. In a multivariate logistic regression model, new DIUR use from Q2 to Q4 of 2013 was not significantly associated with urinary incontinence in Q4, and none of the antihypertensive drug classes were associated with 6-month hospitalization.
In 2013, long-term NH residents treated for hypertension were least likely to receive, more likely to discontinue, and less likely to start a new DIUR than any other first-line antihypertensive medication. DIURs were not associated with increased incontinence or hospitalization, so in the absence of indications for other drugs, DIURs may be a reasonable first-line choice for hypertension treatment in this population.
高血压在超过 50%的美国养老院(NH)居民中发生,但尚不清楚在该人群中,哪些降压药类具有最佳的获益与风险平衡。本研究的目的是描述该人群中降压药物治疗的模式,重点关注噻嗪类利尿剂,并确定噻嗪类利尿剂(DIURs)与 NH 患者重要结局之间的关联。
这是一项在美国所有 NH 中进行的 2013 年第二季度(Q2)接受高血压治疗的长期 NH 居民的观察性队列研究。主要暴露因素是根据医疗保险 Part D 配药数据,按降压治疗类别(DIURs、血管紧张素转换酶抑制剂、血管紧张素受体阻滞剂[ARB]、钙通道阻滞剂和β受体阻滞剂)的使用频率。由于 DIUR 相关的尿症状是关注的焦点,因此排除了使用非噻嗪类利尿剂的居民。我们通过 2013 年 Q2 至 Q4 的医疗保险数据确定了每种药物的持续使用情况,并通过医疗保险索赔和最低数据集确定了 6 个月的尿失禁和住院情况。
在 152902 名接受高血压治疗的 NH 居民中,52.2%接受了β受体阻滞剂(22%为单一药物)治疗,39.7%接受了钙通道阻滞剂(14%为单一药物)治疗,38.8%接受了血管紧张素转换酶抑制剂(14%为单一药物)治疗,38.8%接受了血管紧张素转换酶抑制剂(14%为单一药物)治疗,14.2%接受了 DIURs(2%为单一药物)治疗,13.2%接受了 ARBs(4%为单一药物)治疗。总体而言,55.1%接受了 1 种药物治疗;33.2%接受了 2 种药物治疗;11.8%接受了 3 种或更多药物治疗。从 Q2 到 Q4,与其他 4 类药物(其他 3 类药物的停药率为 14.1%-16.1%)相比,DIURs 的停药率更高(19.4%;所有 P<0.05),与其他任何一类药物相比,DIURs 的起始率都更低,除 ARBs 外(其他 3 类药物的起始率为 3.8%-5.3%)。样本中有 76.6%发生了尿失禁。在多变量逻辑回归模型中,2013 年 Q2 至 Q4 期间新使用 DIUR 与 Q4 时的尿失禁无显著相关性,且任何一种降压药物类别均与 6 个月住院无相关性。
2013 年,接受高血压治疗的长期 NH 居民接受 DIUR 的可能性最小,停止使用 DIUR 的可能性最大,开始使用新 DIUR 的可能性最小。与 DIUR 无关的尿失禁或住院治疗,因此在没有其他药物适应证的情况下,DIUR 可能是该人群高血压治疗的合理一线选择。